期刊文献+

vWF、Ps水平与冠心病中医证型相关性的临床研究 被引量:7

The Clinical Research on the Relation of vWF, Ps level and TCM Syndromes of Coronary Heart Disease
在线阅读 下载PDF
导出
摘要 目的:探讨血管内皮功能指标血管性血友病因子(vWF)、P-选择素(Ps)水平与冠心病中医证型的关系。方法:174例冠心病辨证分为心血瘀阻证、痰阻心脉证、阴寒凝滞证、心肾阴虚证、气阴两虚证、阳气虚衰证6组。同时应用酶联免疫吸附法(ELISA)、流式细胞术检测法分别测定冠心病组和31名健康者对照组血浆vWF、Ps的水平,并对不同证型的指标进行比较。结果:心血瘀阻、痰阻心脉、心肾阴虚、气阴两虚四型血浆vWF、Ps水平较对照组明显升高(P<0.05);心血瘀阻、痰阻心脉二型血浆vWF、Ps水平均高于心肾阴虚、气阴两虚二型(P<0.05),心血瘀阻与痰阻心脉、心肾阴虚与气阴两虚型之间比较无显著性差异(P>0.05)。结论:血浆vWF、Ps水平与冠心病中医辨证分型存在一定相关性。
出处 《湖北中医杂志》 2007年第8期11-12,共2页 Hubei Journal of Traditional Chinese Medicine
  • 相关文献

参考文献12

  • 1Lip GYH,Blann A.von Willebrand fhctor:a marker of endothelial dysfunction in vascular disorders[J].Cardiovase Res,1997,34(2):255-265.
  • 2JMorange Pe,Simon C,Alessi MC,et al.Endothelial cell markers and the risk of coronary heart disease:the Prospective Epidemiological Study of Myocardial Infarction(PRIME)study[J].Circulation,2004,109(11):1343-1348.
  • 3Blann AD,Dobrotova M,Kubisz P,et al.Von willebrand factor,soluble P-selectin,tissue plasminogen activator and plasminogen activator inhibitor in atherosclerosis[J].Thromb Haemost,1995,74:626-630.
  • 4国际心脏病学协会,世界卫生组织临床命名标准化专题组.缺血性心脏病的命名和诊断标准[S].1979.
  • 5中华人民共和国卫生部.中药新药临床研究指导原则[S].,2002..
  • 6Briede JJ,Wielders SJ,Heemskerk JW,et al.von Willebrand factor stimulates thrombin-induced exposure of procoagulant phospholipids on the surface of fibrin-adherent platelets[J].J Thromb Haemost,2003,1(3):559-565.
  • 7Vanhoorelbeke K,Ulrichts H,Schoohneester A,et al.Inhibition of platelet adhesion to collagen as a new target for antithrombotic drugs[J].Curr Drug Targets Cardiovase Haematol Disrod,2003,3(2):125-140.
  • 8谭文锋.冠心病患者血小板活化状态的探讨[J].临床医学,2000,20(12):1-2. 被引量:6
  • 9McEver RP,Beckstead JH,Moore KL.Et al.GMP-140,a platelet a-lpha-granule membrane protein is also synthesized by vascular endothelial cells and is localized in weibel-paladed bodies[J].J Clin Invest,1989,84:92-99.
  • 10KaiKita K,Ogawa H,Yasure H,et al.Soluble P-selectin is released into the coronary circulation after coronary spasm[J].Circulation,1995,92,1726-1730.

二级参考文献13

  • 1张琳,崔让庄,毛用敏,朱天慧.人血DNA的提取方法[J].天津医药,1993,21(2):112-114. 被引量:5
  • 2黄惠勇.冠心病“本虚标虚”病机内涵探析[J].北京中医药大学学报,1994,17(2):10-11. 被引量:18
  • 3Harvey PJ, Keightley AM, Lam YM, et al. A single nucleotide polymorphism at nucleotide - 1793 in the yon willebrand factor regulartory region is associated with plasma vwf :Ag level. Br J Haematol, 2000, 109(2): 349-353.
  • 4Lip GY, Blann AD. von Willebrand factor : a marker of endothelial dysfunction in vascular disorder? Cardiovasc Res 1997,34(2) : 255-265.
  • 5Lip GY, Blann AD. von Willebrand factor and its relevance to cardiovascular disorder. Br Heart J, 1995,74(6) : 580 - 583.
  • 6Kumari M, Marmot M, Brunner E, et al. Social determinants of von willebrand factor: the white study. Arterioscler Thromb Vasc Biol, 2000, 20(7) : 1842-1847.
  • 7Wiman B, Andersson T, Hallqvist J, et al. Plasma level of tissue plasminogen activator/ plasminogen activator inhibitor- 1 complex and von willebrand factor are significant risk markers for recurrent myocardial infarctionin the Stockholm Heart Epidemiology Program(SHEEP) study. Arteriolscler Thromb Vasc Biol, 2000, 20(8) : 2019 - 2023.
  • 8Whincup PH, Danesh MM, Walker, et al. von Willebrand factor and coronary heart disease, prospective study snd meta - analysis. Euro Heart J, 2002, (23):1764-1770.
  • 9Lacquemant C, Gaucher C, Delorme C, et al. Association between high yon willebrand factor level and the Thr789Ala vwf gene polymorphism but not with nephropathy in type I diabetes. The GENEDIAB study group and the DESIR study group. Kidney Int, 2000, 57(4) : 1437 - 1443.
  • 10Jorieux S, Fressinaud E, Goudemand J, et al. Confirmational changes in the D/ domain of yon willebrand factor induced by CYS25 and CYS95 mutations lead to factor VII binding defect and muhimeric impairment. Blood, 1995(10) : 3139-3145.

共引文献63

同被引文献206

引证文献7

二级引证文献69

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部